Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix First data presented for two lead constructs on T-Charge™ Designed to provide fast access to therapy, increased rates of response and longer durability 3 INNOVATION YTB323 is an autologous CD19-directed CAR-T cell therapy in Ph1 for DLBCL and ALL FMC63 podobo CD8 4-1BB CD3-3 YTB323 ■ DLBCL is the most common type of NHL, ~31% of NHL in Western countries ■ Promising initial efficacy results: 73% CR rate at month three in patients with DLBCL (n=16) Preliminary safety profile similar to Kymriah in JULIET study Next steps ■ Ph3 trial in DLBCL to start in 2022 PHE885 is an autologous BCMA-directed CAR-T cell therapy in Ph1 for MM Cancer cell Fully human antiBCMA scFv CD8 BCMA T-cell 4-1BB- CD3 zeta- PHE885 ■ Multiple Myeloma (MM) comprises ~10% of hematologic malignancies ■ Encouraging preliminary data: 100% ORR in r/r MM patients (n=6) Next steps Dose-finding Ph1 study is ongoing ■ Ph2 initiation in 2022 T-Charge TM platform preserves T-cell stemness: May lead to deep and durable responses, improved long-term outcomes, better safety Rapid manufacturing, lower cost of goods and increased scale DLBCL - Diffuse large B cell lymphoma NHL Non-Hodgkin Lymphoma 15 Investor Relations | Q4 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation